Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria and tetanus vaccine
- Development stage
- Unknown
- Lead developer
- Finlay Vaccine Institute
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
diTe-vax is a bivalent toxoid vaccine developed by the Finlay Vaccine Institute for the prevention of diphtheria and tetanus. The vaccine is composed of purified diphtheria and tetanus toxoids, which are toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani* that have been chemically treated to render them non-toxic while maintaining their immunogenicity. These toxoids are adsorbed onto an aluminum hydroxide adjuvant to enhance the immune response. Upon administration, diTe-vax stimulates the production of specific neutralizing antibodies (antitoxins) that provide protection against the systemic effects of diphtheria and tetanus infections. It is typically administered via intramuscular injection and is used for primary immunization or as a booster dose in both children and adults.
- Brand names
- diTe-vax
- Other names
- DT vaccineDiphtheria-Tetanus vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria and tetanus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria and tetanus vaccine.